To develop a PCR assay for Candidatus Mycoplasma haemolamae (CMhl) infection in alpacas and use it to study the efficacy of oxytetracycline treatment and development of a subclinical carrier state.
8 healthy adult alpacas.
Alpacas initially had negative results for CMhl in blood samples via PCR assay and were experimentally infected with CMhl; 4 were treated with oxytetracycline, and 4 were not treated. All were monitored regularly via PCR assay, blood smear examination, PCV, rectal temperature, and physical examination. At 6 months after treatment, all alpacas were immunosuppressed by administration of dexamethasone and tested for CMhl.
7 of 8 alpacas had positive PCR assay results 4 to 6 days after experimental infection. When organisms were detectable on a blood smear, they were seen 2 to 6 days after positive results of PCR assay. Infection was often associated with mild anemia that was usually transient. No alpacas became hypoglycemic. Oxytetracycline treatment was not associated with faster clearance of organisms or resolution of anemia, and 4 of 4 treated alpacas still had positive results of PCR assay when immunosuppressed 6 months later; 0 of 3 nontreated alpacas had positive results of PCR assay following immunosuppression. Transient fever was detected in 3 alpacas during immunosuppression.
The PCR assay was more sensitive than blood smear examination for detection of infection. Clinical signs, anemia, and fever were not necessarily associated with infection. Oxytetracyline administration did not consistently clear CMhl infection. Although treated with oxytetracycline, infected alpacas remained chronic carriers.
"This suggests a component of the dam's immune system is capable of reducing the number of parasites to below the threshold for detection, while producing antibodies specific to this organism. This is also compatible with prior reports (Tornquist et al., 2009, 2011). It is therefore possible that prior infection may provide the immunologic mechanisms necessary to clear infection and protect the newborn that acquires the organism early in life while colostral antibodies are still in circulation. "
[Show abstract][Hide abstract] ABSTRACT: Mycoplasma haemolamae from dam to cria, whether colostral transmission of M. haemolamae
occurs and provide preliminary data on colostral M. haemolamae specific antibody from
pregnant alpacas on a farm with known prevalence of infection. M. haemolamae specific PCR
was performed on blood and colostrum from pregnant alpacas and their cria (n = 52 pairs).
Indirect fluorescent antibody testing was performed on a subset (n = 43) of the colostrum
samples. Total immunoglobulin concentrations of colostrum and cria sera and M. haemolamae
specific IgG (prior to and after ingesting colostrum) were determined by turbidometric
immunoassay and indirect fluorescence antibody testing respectively. Sixteen of 52 dams
(30.7%) pre-partum and one of 52 cria post-partum (1.9%; prior to ingesting colostrum)
were PCR positive for M. haemolamae, while 36/52 dams (69%) and 51/52 cria (98%) tested
negative for M. haemolamae by PCR. All 43 colostrum samples and 52 of 52 post-colostrum
cria blood samples (100%) were negative by PCR. The dam giving birth to the M. haemolamae
PCR positive cria was PCR negative. Statistically, it was no more likely for a PCR positive
dam to give birth to a M. haemolamae, PCR positive cria (prior to colostrum ingestion) than
a PCR negative dam (p = 0.3077). M. haemolamae specific IgG was present in 22 of 43 (51%)
of colostrum samples at a 1:10 dilution and 14 of 22 (64%) at a 1:100 dilution. There was no
relationship between the PCR status of the dam and whether or not M. haemolamae specific
antibodies were present in colostrum. Among the animals tested, in utero transmission of
M. haemolamae was rare (1/52 pre-colostral alpaca cria), and all colostrum samples were
negative for M. haemolamae by PCR. These data indicate that colostrum from positive dams
is unlikely to harbor this parasite and therefore does not serve as a source of infection
to newborn cria. Colostrum derived from both PCR positive and negative dams contained
M. haemolamae specific antibodies. Our findings suggest that M. haemolamae specific antibodies
may play a role in immunity to this hemoparasite; however, challenge studies are
necessary to fully evaluate the role of M. haemolamae specific antibodies. Furthermore, antibody
prevalence and detectable titers may provide different estimates than those available
from current PCR based prevalence studies. Our findings also suggest that M. haemolamae
isolates from geographically distinct regions do not differ significantly from each other.
Small Ruminant Research 08/2012; 106(2-3):181-188. DOI:10.1016/j.smallrumres.2012.02.021 · 1.13 Impact Factor
"Most recently, a real-time PCR method based on the SYBR Green principle has been published that permits initial screening for suspected hemoplasma infection in a broad range of mammalian species (Willi et al., 2009). The assay described herein allows quantification of bacterial burden with a sensitivity of one copy per 5 ml of blood, which is more sensitive than what had been published for a conventional CMhl PCR assay (Tornquist et al., 2009). The analytical specificity of the CMhl real-time TaqMan 1 PCR assay predicted in silico was confirmed by testing DNA from different hemotropic and non-hemotropic mycoplasma species. "
[Show abstract][Hide abstract] ABSTRACT: Two alpacas from a herd in southwest Switzerland died for unknown reasons. Necropsy revealed chronic weight loss and pale mucous membranes. Infection with hemotropic mycoplasmas was suspected and subsequently confirmed by molecular methods. In order to investigate the epidemiological situation in this herd, a real-time TaqMan(®) qPCR assay for the specific detection and quantification of hemoplasma infection in South American camelids was developed. This assay was based on the 16S rRNA gene and amplified 'Candidatus Mycoplasma haemolamae' DNA, but not DNA from other hemoplasmas or non-hemotropic mycoplasma species. The lower detection limit was one copy/PCR, and the amplification efficiency was 97.4%. In 11 out of 24 clinically healthy herd mates of the two infected alpacas, 'Candidatus M. haemolamae' infection was confirmed. No correlation was found between bacterial load and clinical signs or anemia. The assay described herein enables to detect and quantify 'Candidatus M. haemolamae' and may be used in future studies to investigate the prevalence, pathogenesis and treatment follow-up of hemoplasma infections in South American camelids.
[Show abstract][Hide abstract] ABSTRACT: Mycoplasma haemocanis is a hemotropic bacterium that can be associated with acute hemolytic disease in immunocompromised or splenectomized dogs. The present case report describes for the first time the use of real-time quantitative polymerase chain reaction (qPCR) to monitor M. haemocanis infection in a splenectomized dog. The report also describes the application of real-time qPCR for the analysis of deoxyribonucleic acid extracted from stained blood films. The analysis of blood films from the time of initial presentation allowed a retrospective confirmation of M. haemocanis infection. The M. haemocanis copy numbers remained high throughout antibiotic treatment of this dog. A decline in copy numbers was only recorded after 11 months of therapy, when improvements in clinical and hematological indices were also noted. Clearance of infection was not achieved, and the dog remained positive for M. haemocanis at 3.5 months postcessation of antibiotic therapy. Cytological examination of blood films for the presence of organisms was insensitive for the detection of parasitemia.
Journal of veterinary diagnostic investigation: official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 07/2010; 22(4):582-7. DOI:10.1177/104063871002200413 · 1.35 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.